Idenix Pharmaceuticals, Inc. Announces Declaration Of Senior Party In A Second Patent Interference By The USPTO

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the United States Patent and Trademark Office (USPTO) declared a patent interference between Idenix's U.S. Patent 7,608,600 and Gilead Sciences, Inc.'s U.S. Patent Application 11/854,218, both related to the use of certain 2'-methyl, 2'-fluoro nucleoside compounds to treat hepatitis C virus (HCV) infections.

Help employers find you! Check out all the jobs and post your resume.

Back to news